Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Savara from “hold” to “sell,” though the broader analyst consensus remains “Moderate Buy” with a $10.14 price target.
• Savara opened at $5.38 and recently reported a quarterly loss of $0.16 per share, missing expectations by $0.02; analysts expect a full-year loss of $0.62 per share.
• Analysts have reduced Savara’s earnings forecasts through 2030, signaling continued losses despite eventual projected profitability. Institutional investors own approximately 87.93% of the company.

Savara (NASDAQ:SVRA - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

A number of other research analysts have also recently weighed in on SVRA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. Oppenheimer assumed coverage on shares of Savara in a report on Friday, April 24th. They issued an "outperform" rating and a $11.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $10.14.

Savara Price Performance

NASDAQ SVRA opened at $5.38 on Friday. The company has a market capitalization of $1.11 billion, a PE ratio of -9.28 and a beta of 0.29. The company has a debt-to-equity ratio of 0.21, a quick ratio of 13.47 and a current ratio of 10.13. The business's fifty day moving average is $5.65 and its 200 day moving average is $5.48. Savara has a fifty-two week low of $2.92 and a fifty-two week high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Sell-side analysts predict that Savara will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Large investors have recently made changes to their positions in the company. Prudential Financial Inc. purchased a new stake in shares of Savara in the second quarter worth about $30,000. BNP Paribas Financial Markets boosted its position in shares of Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after acquiring an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP bought a new position in shares of Savara during the 2nd quarter valued at approximately $33,000. Russell Investments Group Ltd. boosted its position in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after acquiring an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Savara in the third quarter valued at $44,000. 87.93% of the stock is owned by institutional investors.

Trending Headlines about Savara

Here are the key news stories impacting Savara this week:

• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.62 from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter.
• Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of $0.37 from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years.
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook.
• Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source